公开(公告)号：US09782401B1

公开(公告)日：2017-10-10

申请号：US15142373

申请日：2016-04-29

Applicant: Macau University of Science and Technology

Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Cheng-Yu Chen ,  Guo-Yuan Zhu

IPC: A61K36/24 ,  A61K31/4745

CPC classification number: A61K31/4745 ,  A61K36/24

Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

公开(公告)号：US20170312266A1

公开(公告)日：2017-11-02

申请号：US15142373

申请日：2016-04-29

Applicant: Macau University of Science and Technology

Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Cheng-Yu Chen ,  Guo-Yuan Zhu

IPC: A61K31/4745 ,  A61K36/24

CPC classification number: A61K31/4745 ,  A61K36/24

Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.

公开(公告)号：US10900966B2

公开(公告)日：2021-01-26

申请号：US16281122

申请日：2019-02-21

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Jing-Rong Wang ,  Weina Gao ,  Leefong Yau ,  Hao Huang ,  Qiong Meng ,  Tiantian Tong ,  Zhi-Hong Jiang

IPC: G01N33/564 ,  G01N33/48 ,  G01N1/40 ,  G01N30/08 ,  G01N30/60 ,  B01L3/00 ,  G01N30/72 ,  G01N30/88

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

公开(公告)号：US20170281702A1

公开(公告)日：2017-10-05

申请号：US15089687

申请日：2016-04-04

Applicant: Macau University of Science and Technology

Inventor： Jing-Rong Wang ,  Zhi-Hong Jiang ,  Qi-Tong Feng ,  Guo-Yuan Zhu ,  Wei-Na Gao ,  Zifeng Yang ,  Nanshan Zhong

IPC: A61K36/19 ,  A61K31/7056 ,  A61K31/192 ,  A61K31/404 ,  A61K31/047 ,  A61K31/191 ,  A61K31/538 ,  A61K31/517

CPC classification number: A61K36/19 ,  A61K31/404 ,  A61K31/538 ,  A61K31/567 ,  A61K2236/15 ,  A61K2236/17 ,  A61K2236/33 ,  A61K2236/55

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

公开(公告)号：US10278966B2

公开(公告)日：2019-05-07

申请号：US15142407

申请日：2016-04-29

Applicant: Macau University of Science and Technology

Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Cheng-Yu Chen ,  Guo-Yuan Zhu

IPC: A61K31/4745 ,  A61K36/27

Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

公开(公告)号：US20170312267A1

公开(公告)日：2017-11-02

申请号：US15142407

申请日：2016-04-29

Applicant: Macau University of Science and Technology

Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Cheng-Yu Chen ,  Guo-Yuan Zhu

IPC: A61K31/4745 ,  A61K36/24

CPC classification number: A61K31/4745 ,  A61K36/27

Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.

公开(公告)号：US11357806B2

公开(公告)日：2022-06-14

申请号：US15131218

申请日：2016-04-18

Applicant: Macau University of Science and Technology

Inventor： Zhi-Hong Jiang ,  Jing-Rong Wang ,  Jia-Ning Mi ,  Junping Kou ,  Yuwei Han ,  Yingqiong Xu

IPC: A61K36/068 ,  A61K31/133 ,  A61K31/164 ,  A61K31/688 ,  G01N30/34 ,  G01N30/72 ,  B01D15/42 ,  C12Q1/04 ,  G01N33/92 ,  G01N30/00 ,  G01N30/02

Abstract: A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject. Still further in accordance with the present invention is a composition, in particular a pharmaceutical composition comprising at least one sphingolipid portion.

公开(公告)号：US10537601B2

公开(公告)日：2020-01-21

申请号：US15089687

申请日：2016-04-04

Applicant: Macau University of Science and Technology

Inventor： Jing-Rong Wang ,  Zhi-Hong Jiang ,  Qi-Tong Feng ,  Guo-Yuan Zhu ,  Wei-Na Gao ,  Zifeng Yang ,  Nanshan Zhong

IPC: A61K36/19 ,  A61K31/47 ,  A61K31/191 ,  A61K31/192 ,  A61K31/404 ,  A61K31/517 ,  A61K31/538 ,  A61K31/7056 ,  A61K31/567

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

公开(公告)号：US10234454B2

公开(公告)日：2019-03-19

申请号：US14883622

申请日：2015-10-15

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Jing-Rong Wang ,  Weina Gao ,  Leefong Yau ,  Hao Huang ,  Qiong Meng ,  Tiantian Tong ,  Zhi-Hong Jiang

IPC: G01N33/564 ,  G01N33/48 ,  G01N30/08 ,  B01L3/00 ,  G01N1/40 ,  G01N30/60 ,  G01N30/72 ,  G01N30/88

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

公开(公告)号：US10039797B2

公开(公告)日：2018-08-07

申请号：US15131243

申请日：2016-04-18

Applicant: Macau University of Science and Technology

Inventor： Jing-Rong Wang ,  Jia-Ning Mi ,  Zhi-Hong Jiang

IPC: A61K36/068 ,  A61K31/133 ,  A61K31/164 ,  A61K31/688 ,  B01D15/42 ,  C12Q1/04 ,  G01N30/02 ,  G01N30/72 ,  G01N33/92

Abstract: A method of identifying and preferably quantifying at least one sphingolipid, in particular the sphingolipid portion in wild-type Cordyceps or Cordyceps derivates includes preparing a test sample solution from a Cordyceps sample, subjecting the test sample solution to liquid chromatrography with a mobile phase including at least a first and second eluting solvent; and performing a mass spectrometry after the step of subjecting. The quality and safety of Cordyceps products can be determined and wild-type Cordyceps and Cordyceps derivates may be differentiated via the ratio and/or presence of certain sphingolipids especially suitable as markers.